Table 3 Treatment regimens used in this retrospective study

From: BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome

First-line regimens

N (out of 144)

%

FOLFOX+Bevacizumab

33

23

FOLFOX+Cetuximab

9

6

FOLFOXIRI

67

46

FOLFIRI

27

19

FOLFOX

8

6

Oxaliplatin-based treatment (first line)

117

82

Irinotecan-based treatment (first line)

94

65

Bevacizumab+chemotherapy (first line)

33

23

Oxaliplatin-based treatment (any line)

128

89

Irinotecan-based treatment (any line)

123

85

Bevacizumab+chemotherapy (any line)

74

51

Cetuximab+chemotherapy (any line)

69

48

Patients treated with all 3 chemotherapy drugs

126

87

Patients treated with all 5 active agents

65

45

  1. Abbreviations: FOLFOX=folinic acid, 5FU, oxaliplatin; FOLFIRI=folinic acid, 5FU, irinotecan; FOLFOXIRI=folinic acid, 5FU, oxaliplatin, irinotecan.
Back to article page